MaxCyte (NASDAQ:MXCT – Get Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 159.37% from the company’s previous close.
MaxCyte Stock Up 1.5 %
MXCT opened at $3.47 on Wednesday. The firm’s 50-day moving average price is $4.23 and its 200-day moving average price is $3.99. MaxCyte has a 52-week low of $3.16 and a 52-week high of $5.26. The company has a market cap of $367.68 million, a P/E ratio of -10.21 and a beta of 1.35.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of MXCT. Tower Research Capital LLC TRC increased its holdings in MaxCyte by 123.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock valued at $31,000 after buying an additional 4,173 shares in the last quarter. Intech Investment Management LLC acquired a new position in MaxCyte during the third quarter worth $51,000. BNP Paribas Financial Markets purchased a new stake in shares of MaxCyte during the fourth quarter worth about $56,000. Prudential Financial Inc. acquired a new stake in MaxCyte in the 4th quarter worth about $65,000. Finally, Catalyst Funds Management Pty Ltd acquired a new position in MaxCyte in the 4th quarter valued at $74,000. 68.81% of the stock is owned by institutional investors and hedge funds.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
- Five stocks we like better than MaxCyte
- Where Do I Find 52-Week Highs and Lows?
- 3 Retail Giants React to Tariffs—What It Means for Consumers
- What Are Treasury Bonds?
- Rockwell Automation Poised to Gain From U.S. Tariffs & Onshoring
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Companies Buying Back Stock—Why It Matters
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
